Testing a cholesterol-lowering drug after stroke clot removal
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests if adding a PCSK9 inhibitor (a newer cholesterol-lowering medicine) to standard care helps people who had a stroke from a large artery blockage and had a clot-removal procedure. It may lower bad cholesterol further and reduce the risk of another stroke.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You had a stroke caused by a blocked large artery in the front of your brain and a procedure to remove the clot.
- Your LDL (bad) cholesterol is above a certain level (1.8 mmol/L) or your non-HDL cholesterol is above 2.6 mmol/L.
- You had little or no disability before this stroke (able to carry out daily activities without help).
- You have not used a PCSK9 inhibitor (like evolocumab or alirocumab) in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a cholesterol-lowering medication called evolocumab (a PCSK9 inhibitor) can help people recover better after a specific type of stroke caused by clogged arteries. The study checks if lowering cholesterol further than usual statins do improves stroke outcomes and is safe.
This trial tests whether quickly starting an aggressive cholesterol-lowering treatment after a stroke improves recovery. It is for people who are about to have a procedure to remove a large blood clot from their brain.
This trial tests whether a cholesterol-lowering medication (PCSK9 inhibitor) can help prevent further strokes in people who have recently had a stroke or mini-stroke due to a narrowed artery in the brain. It is for adults 30 to 80 years old who meet specific health criteria.
This trial tests whether giving a PCSK9 inhibitor (a type of cholesterol-lowering medicine) early after a stroke can improve recovery and lower 'bad' cholesterol. It is for people who have had a non-cardioembolic stroke (not from a heart problem) caused by hardening of the arteries.
This trial tests whether a PCSK9 inhibitor (a drug that lowers cholesterol) can help people who recently had a stroke caused by narrowing of an artery inside the skull. It aims to see if the drug can prevent more strokes and improve recovery.
This study looks at strategies to improve cholesterol treatment in adults whose brain arteries are narrowed and who have had symptoms. Better cholesterol management may help reduce future problems related to this condition.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.